The stock of Mira Pharmaceuticals Inc (MIRA) has seen a -6.30% decrease in the past week, with a -36.36% drop in the past month, and a -23.23% decrease in the past quarter. The volatility ratio for the week is 9.00%, and the volatility levels for the past 30 days are at 10.77% for MIRA. The simple moving average for the past 20 days is -15.71% for MIRA’s stock, with a -4.02% simple moving average for the past 200 days.
Is It Worth Investing in Mira Pharmaceuticals Inc (NASDAQ: MIRA) Right Now?
The 36-month beta value for MIRA is at 2.00. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MIRA is 10.95M, and currently, shorts hold a 6.66% of that float. The average trading volume for MIRA on December 06, 2024 was 1.47M shares.
MIRA) stock’s latest price update
Mira Pharmaceuticals Inc (NASDAQ: MIRA) has experienced a decline in its stock price by -7.03 compared to its previous closing price of 1.28. However, the company has seen a fall of -6.30% in its stock price over the last five trading days. accesswire.com reported 2024-11-20 that Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment MIAMI, FL / ACCESSWIRE / November 20, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company, is pleased to announce the selection of The Centre for Human Drug Research (CHDR) in Leiden, The Netherlands, as the site for its Phase I/IIa clinical trial of Ketamir-2, a novel oral ketamine analog. Recruitment for the trial is set to begin in Q1 2025, with initial safety and efficacy results from the Phase I study in healthy subjects expected in the second half of 2025.
MIRA Trading at -12.45% from the 50-Day Moving Average
After a stumble in the market that brought MIRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.25% of loss for the given period.
Volatility was left at 10.77%, however, over the last 30 days, the volatility rate increased by 9.00%, as shares sank -30.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.18% upper at present.
During the last 5 trading sessions, MIRA fell by -6.30%, which changed the moving average for the period of 200-days by +10.19% in comparison to the 20-day moving average, which settled at $1.4117. In addition, Mira Pharmaceuticals Inc saw 13.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MIRA starting from Aminov Erez, who sale 55,410 shares at the price of $1.39 back on Nov 19 ’24. After this action, Aminov Erez now owns 1,105,790 shares of Mira Pharmaceuticals Inc, valued at $77,020 using the latest closing price.
Aminov Erez, the Chief Executive Officer of Mira Pharmaceuticals Inc, sale 44,590 shares at $1.27 during a trade that took place back on Nov 20 ’24, which means that Aminov Erez is holding 1,061,200 shares at $56,629 based on the most recent closing price.
Stock Fundamentals for MIRA
The total capital return value is set at -3.0. Equity return is now at value -192.32, with -169.22 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.11.
Conclusion
In conclusion, Mira Pharmaceuticals Inc (MIRA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
